Acrivon Therapeutics held a KOL panel on February 27, 2026, at the ESGO Congress disclosing interim data from the ACR-368 Phase 2b registrational-intent trial (ACR-368-201/GOG3082) in endometrial cancer. Arm 1 (BM+ cohort, N=40) showed ORR of 39% (95% CI 24-56), DCR 80.6%, with favorable safety and high activity in serous subtype.
Key takeaways
KOL panel presented interim ACR-368 data from Arm 1 (BM+, N=40): ORR 39% (95% CI 24-56), DCR 80.6%, CBR 61.3%
ORR 44% in BM+ patients with ≤2 prior lines (N=35); 52% in serous subtype with ≤2 prior lines (N=23)
Favorable safety: Grades 3/4 TRAEs include anemia 27%, neutropenia 25%, thrombocytopenia 22%; no fatal TRAEs
Arm 2 (BM-, N=48): ACR-368 + ULDG; Arm 3 serous all-comer (N=~90) enrolling with completion Q4 2026
Patients: relapsed after platinum and anti-PD-(L)1; median 2 prior lines; 50% serous in Arm 1
Study expanded to >20 EU sites; primary endpoint ORR by RECIST 1.1